结直肠癌患者的免疫检查点抑制剂:错配修复缺陷和观点

IF 2.7 Q3 ONCOLOGY

Colorectal Cancer Pub Date : 2017-06-21 DOI:10.2217/CRC-2017-0004

R. Cohen, M. Svrcek, A. Duval, Y. Parc, P. Österlund, T. André

{"title":"结直肠癌患者的免疫检查点抑制剂:错配修复缺陷和观点","authors":"R. Cohen, M. Svrcek, A. Duval, Y. Parc, P. Österlund, T. André","doi":"10.2217/CRC-2017-0004","DOIUrl":null,"url":null,"abstract":"Harnessing the immune system to fight tumor cells is becoming a promising and innovative therapeutic strategy for a large spectrum of malignancies. The evaluation of immunotherapy in the context of colorectal cancers (CRCs) has brought to light mismatch repair deficiency as a major predictive biomarker for the efficacy of immune checkpoint blockade. In this review, we summarize the promising results of immune checkpoint inhibitors for patients with metastatic CRCs harboring mismatch repair deficiency, with special emphasis on further clinical development. Given the biological determinants of sensitivity to immune checkpoint blockade, we will also elucidate points that could unlock the potential of immunotherapy for patients with mismatch repair-proficient CRC.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"23-31"},"PeriodicalIF":2.7000,"publicationDate":"2017-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0004","citationCount":"3","resultStr":"{\"title\":\"Immune checkpoint inhibitors for patients with colorectal cancer: mismatch repair deficiency and perspectives\",\"authors\":\"R. Cohen, M. Svrcek, A. Duval, Y. Parc, P. Österlund, T. André\",\"doi\":\"10.2217/CRC-2017-0004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Harnessing the immune system to fight tumor cells is becoming a promising and innovative therapeutic strategy for a large spectrum of malignancies. The evaluation of immunotherapy in the context of colorectal cancers (CRCs) has brought to light mismatch repair deficiency as a major predictive biomarker for the efficacy of immune checkpoint blockade. In this review, we summarize the promising results of immune checkpoint inhibitors for patients with metastatic CRCs harboring mismatch repair deficiency, with special emphasis on further clinical development. Given the biological determinants of sensitivity to immune checkpoint blockade, we will also elucidate points that could unlock the potential of immunotherapy for patients with mismatch repair-proficient CRC.\",\"PeriodicalId\":43638,\"journal\":{\"name\":\"Colorectal Cancer\",\"volume\":\"6 1\",\"pages\":\"23-31\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2017-06-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/CRC-2017-0004\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Colorectal Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/CRC-2017-0004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colorectal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/CRC-2017-0004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 3

摘要

利用免疫系统对抗肿瘤细胞正成为一种有前途的创新治疗策略，用于治疗各种恶性肿瘤。在结直肠癌（CRC）背景下对免疫疗法的评估表明，错配修复缺陷是免疫检查点阻断疗效的主要预测生物标志物。在这篇综述中，我们总结了免疫检查点抑制剂治疗具有错配修复缺陷的转移性CRC患者的有希望的结果，并特别强调了进一步的临床发展。考虑到对免疫检查点阻断敏感的生物学决定因素，我们还将阐明可以为精通错配修复的CRC患者释放免疫疗法潜力的要点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Immune checkpoint inhibitors for patients with colorectal cancer: mismatch repair deficiency and perspectives

Harnessing the immune system to fight tumor cells is becoming a promising and innovative therapeutic strategy for a large spectrum of malignancies. The evaluation of immunotherapy in the context of colorectal cancers (CRCs) has brought to light mismatch repair deficiency as a major predictive biomarker for the efficacy of immune checkpoint blockade. In this review, we summarize the promising results of immune checkpoint inhibitors for patients with metastatic CRCs harboring mismatch repair deficiency, with special emphasis on further clinical development. Given the biological determinants of sensitivity to immune checkpoint blockade, we will also elucidate points that could unlock the potential of immunotherapy for patients with mismatch repair-proficient CRC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Colorectal Cancer ONCOLOGY-

自引率

0.00%

发文量

期刊介绍： Colorectal cancer is a major cause of morbidity and mortality, particularly in the developed world. Risk factors for colorectal cancer are on the rise in many countries; populations are aging, and obesity and diabetes are increasing. National screening programs are helping to detect cancer while it is still curable; however, colorectal cancer remains the third leading cause of cancer deaths in the USA and options are still limited for those with more advanced disease. Consequently, colorectal cancer is a major research priority for government, pharmaceutical companies and non-profit organizations. Research into diagnosis and optimum treatment of the disease is progressing rapidly, with new advances reported every day. Colorectal Cancer presents reviews, analysis and commentary. on all aspects of colorectal cancer.